Scholarlink

<p>The past year has continued the rapid evolution of diabetes technology across the monitoring, delivery, analytics, and patient-support domains. Improvements in continuous glucose monitoring (CGM) accuracy and wear-time options, widening use and regulatory expansion of automated insulin delivery (AID) systems, growth in connected insulin pens, maturation of digital therapeutics, and an influx of artificial intelligence (AI)-driven decision support tools have together shifted diabetes care toward tighter, more personalized, and more remote models of management. At the same time, device safety events, persistent affordability and access gaps, and data-interoperability and privacy challenges remind clinicians and policymakers that technology alone is not a panacea. This review summarizes the most important developments from last year (2025), highlights evidence from recent trials and regulatory actions, and discusses implications for practice and future directions.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Technology in Diabetes: A Year in Review

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年4月21日

查看全文
  • Subhankar Chatterjee,
  • Subhodip Pramanik,
  • Nitin Kapoor,
  • Sanjay Kalra

摘要

The past year has continued the rapid evolution of diabetes technology across the monitoring, delivery, analytics, and patient-support domains. Improvements in continuous glucose monitoring (CGM) accuracy and wear-time options, widening use and regulatory expansion of automated insulin delivery (AID) systems, growth in connected insulin pens, maturation of digital therapeutics, and an influx of artificial intelligence (AI)-driven decision support tools have together shifted diabetes care toward tighter, more personalized, and more remote models of management. At the same time, device safety events, persistent affordability and access gaps, and data-interoperability and privacy challenges remind clinicians and policymakers that technology alone is not a panacea. This review summarizes the most important developments from last year (2025), highlights evidence from recent trials and regulatory actions, and discusses implications for practice and future directions.